Kowa Company

What Kowa Company does

Kowa Company, Ltd. is a privately held Japanese multinational conglomerate founded in 1894 and headquartered in Nagoya, with group turnover of 459.552 billion JPY (approximately $3 billion USD) and approximately 7,900 employees worldwide. The company operates across five primary divisions: Kowa Pharmaceuticals (cardiometabolic therapeutics and a developing ophthalmology and oncology pipeline including NCX 470, a nitric oxide-donating bimatoprost eye drop with NDA submitted to the FDA in July 2026, and K-679, a proprietary antibody drug-loaded unimicelle conjugate with ultra-high drug-to-antibody ratio of approximately 45 DM1 per antibody); Kowa Optimed (lenses for CCTV and machine vision, sporting optics, and medical optics, operating since 1952); Kowa Chemicals (specialty sourcing and distribution of industrial chemicals, food ingredients, dental products, cosmetics, and activated carbon with over 30 years of European market presence); Kowa LED Lighting (industrial lighting with approximately 4,000 installations in Japan, planning European expansion); and Kowa Medical.

Kowa generates revenue through a diversified mix of channels including direct B2B sales to European industrial customers via Kowa Europe GmbH in Düsseldorf, licensing royalties and milestone payments from pharmaceutical partnerships (notably the exclusive US licensing arrangement with Nicox for NCX 470, which triggered a $3.3 million milestone payment upon NDA submission), hardware sales of optical products and LED lighting, and transaction-fee-based specialty chemical distribution. The customer base spans glaucoma and ocular hypertension patients, EGFR-expressing solid tumor patients, European industrial chemical buyers, and industrial vision/sporting optics consumers. As exclusive US licensee for Nicox's NCX 470, Kowa is positioned to enter the US ophthalmology market with commercial launch targeted before end of 2027, pending FDA approval expected by mid-2027.

Kowa holds a minority financial stake of approximately 42.2% (combined with DIC Corporation and Oasis Management) in Taiyo Holdings Co., Ltd., supporting KKR's tender offer to take the company private at ¥4,750 per share in a transaction valued at approximately $3.2 billion. The company's competitive advantages include 130 years of brand heritage, deep sourcing relationships with Japanese manufacturers, proprietary pharmaceutical technology platforms, and a diversified revenue base that reduces single-market exposure. No public ticker exists, and the company remains privately held under Japanese corporate structure.

Name

Kowa Company

Legal name

Kowa Co., Ltd.

Website

https://www.kowaeurope.de

Company type

Private

Founded year

1894

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Kowa Company is a privately held Japanese multinational founded in 1894, operating across pharmaceuticals, specialty chemicals, optics, LED lighting, and medical devices with approximately 7,900 employees and 459.552 billion JPY in group turnover, serving industrial, healthcare, and consumer markets globally.

Ownership category

akta.pro rank

Product category

Diversified Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Ophthalmic Goods Manufacturing (339115), Chemical Manufacturing (325), Electric Lighting Equipment Manufacturing (33513)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851), Optical Instruments & Lenses (3827), Miscellaneous Chemical Products (2890), Electric Lighting & Wiring Equipment (3640)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Pharmaceutical manufacturing
• Optical lens products
• Specialty chemicals distribution
• Industrial LED lighting
• Medical optics devices

Headquarters

HQ city

Nagoya

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: Kowa receives milestone payments and royalties from pharmaceutical licensing agreements, including the Nicox NCX 470 licensing deal where Kowa submitted NDA to FDA triggering a $3.3 million milestone payment.
2. Pharmaceuticals: Development and commercialization of cardiometabolic therapeutics through Kowa Pharma, novel drug candidates including K-679 antibody drug conjugate.
3. Chemicals Trading: Specialty sourcing and distribution of industrial chemicals, food ingredients, dental products, cosmetics, and activated carbon for European customers.
4. Optics Products: Sale of lenses for CCTV and machine vision, sporting optics, medical optics, and LED lighting solutions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Kowa Company manufactures and sells pharmaceutical therapeutics (cardiometabolic drugs and ophthalmology candidates such as NCX 470 and K-679), optical products (CCTV, machine vision, sporting, and medical optics), specialty chemicals (industrial chemicals, food ingredients, dental, cosmetics, and activated carbon), and industrial LED lighting. The company operates multiple divisions including Kowa Optimed, Kowa Chemicals, Kowa Pharmaceuticals, Kowa Medical, and Kowa LED Lighting, with operations across Japan, Europe, and North America.

Product overview

Kowa Company is a multinational Japanese company established in 1894 with diverse operations in pharmaceuticals, life science, information technology, chemicals, optics, LED lighting, textiles, machinery, and consumer products. The company operates through several divisions: Kowa Optimed (lenses for CCTV/machine vision, sporting optics, medical optics), Kowa Chemicals (industrial chemicals, food ingredients, dental, cosmetics, activated carbon), Kowa Pharmaceuticals (cardiometabolic therapeutics), and Kowa LED Lighting (industrial lighting). The company is also advancing pharmaceutical candidates including NCX 470 (novel eye drop for glaucoma, NDA submitted to FDA) and K-679 (antibody drug conjugate for solid tumors in nonclinical development).

Differentiator

Problem solved

Functional benefit

Brands

• Kowa Optimed: Electronics and Optics division producing lenses, sporting optics, and medical optics products since 1952
• Kowa Chemicals
• Kowa Pharmaceuticals
• Kowa Lenses
• Kowa Sporting Optics
• Kowa LED Lighting

Products and services

• NCX 470 Novel nitric oxide-donating bimatoprost eye drop designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension, based on positive Phase 3 data from Mont Blanc and Denali trials. Licensed from Nicox SA with Kowa as exclusive US licensee.
• K-679 Novel antibody drug-loaded unimicelle conjugate (ADUC) using proprietary micelle technology achieving ultra-high drug-to-antibody ratio (DAR) of approximately 45 DM1 molecules per antibody for EGFR-expressing solid tumors including colorectal cancer.
• Kowa Lenses CCTV and machine vision lens product lines, among the most extensive in the market, with custom lens solutions available for specialized applications.
• Kowa Sporting Optics High-quality spotting scopes and sporting optics products appreciated for their quality and reliability. Production began in 1952 through the Optimed division.
• Kowa Medical Optics Medical optical equipment and devices for medical and healthcare applications.
• Kowa LED Lighting Industrial LED lighting products with approximately 4,000 installations nationwide in Japan, positioned as one of Japan's major players in industrial lighting and expanding into Europe.
• Specialty Chemicals Portfolio Specialty sourcing and distribution of industrial chemicals, food ingredients, dental products, cosmetics, and activated carbon for European customers through Kowa Europe GmbH's long-standing relationships with manufacturers in Japan and sourcing network in China and India.
• Kowa Pharmaceuticals Cardiometabolic therapeutics development and delivery, committed to safe and effective solutions with high ethical and professional standards.

Quantifiable outcome

• Up to 10mmHg intraocular pressure reduction demonstrated in Phase 3 Mont Blanc and Denali trials
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Nicox SAcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2026Kowa Company is the exclusive US licensee for Nicox's NCX 470, a novel nitric oxide-donating bimatoprost eye drop for open-angle glaucoma. Kowa submitted the New Drug Application (NDA) to the FDA, triggering a $3.3 million milestone payment to Nicox. The partnership provides Kowa with commercial rights in the US market, with potential approval by mid-2027 and commercial launch before end of 2027.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bausch + Lomb (Bausch Health): Global ophthalmology player with a leading portfolio of glaucoma therapeutics (including PGA-based products like Vyzulta and Lumigan franchises) and a broad medical optics/surgical vision device business — directly comparable to Kowa's NCX 470 in glaucoma and to Kowa Optimed in ophthalmic optics.
• Leica Camera: Premium sporting optics, spotting scope, and optical instruments manufacturer. Direct comparable to Kowa Sporting Optics in the high-end observation optics segment.
• Santen Pharmaceutical: Japan-based specialty ophthalmology pharmaceutical company with a leading glaucoma franchise (including prostaglandin analogs and rock inhibitors). Most direct competitor to Kowa's NCX 470 given overlapping therapeutic focus, geography, and patient population.
• Nicox SA: French ophthalmology R&D company whose lead asset NCX 470 is licensed exclusively to Kowa for the US. Highly comparable development pipeline focus on nitric-oxide-donating prostaglandin analogs for glaucoma/ocular hypertension.

Broad incumbents

• Allergan / AbbVie: Owner of the Lumigan franchise and other leading glaucoma therapeutics via the Allergan Aesthetics/Eye Care portfolio. The dominant commercial benchmark Kowa must displace with NCX 470 in the US open-angle glaucoma market.
• Daiichi Sankyo: Japanese pharma major with the leading next-generation ADC franchise (Enhertu, Datroway) targeting HER2 and other tumor antigens. The most relevant large-cap benchmark for Kowa's ADUC micelle platform and K-679 program.
• Nikon: Japanese optical instruments conglomerate with significant industrial optics, machine vision, and sporting optics exposure. Broad incumbent comparable to Kowa Optimed's CCTV/machine vision and spotting scope product lines.
• Brenntag: Global market leader in chemical distribution, with a sizable specialty chemicals portfolio spanning food, personal care, and industrial applications. Comparable to Kowa Chemicals' specialty chemicals distribution business in Europe.
• Carl Zeiss (ZEISS Group): German optics and optoelectronics incumbent with extensive lens, sporting optics, and medical optics portfolios. Broad incumbent comparable to Kowa Optimed across machine vision, sporting, and medical optics categories.

Emerging players

• Aerie Pharmaceuticals: Specialty ophthalmology company focused on novel glaucoma therapies (Rhopressa, Rocklatan). Direct therapeutic-area overlap with Kowa's NCX 470, though Aerie is currently private/divested and smaller in commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kowa-europe-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kowa Company